2024-06-03 04:50:00 ET
Moderna (NASDAQ: MRNA) jumped into the limelight when it started developing a coronavirus vaccine candidate. And the stock soared as the vaccine raced across the finish line and went on to bring in billions of dollars in earnings.
But in later pandemic days, investors started worrying about Moderna's dependence on its only commercialized product, and that has weighed on the stock price. Shares of the biotech company have dropped 70% from their high back in 2021.
Moderna might be about to enter a new phase of growth, though. Its investors just got some bullish news last week -- news that could unlock a $10 billion market for the company. Let's check out the details.
For further details see:
Moderna Investors Just Got Some Bullish News